Commentary & Deal Flow

• Price Progression:
• • IPT: High 3s, par
• Issuer: Neopharmed Gentili S.p.A.
• Ticker: NEGENT
• Size: EUR425m
• Format: 144A/Reg S; No Reg Rights
• Security: Senior Secured FRN due 2033 (7y)
• Expected Corporate Ratings (M/S/F): B3 (positive) / B (stable) / B (stable)
• Expected Issue Ratings (M/S/F): B3 / B / B
• Optional Redemption: NC1 (par)
• Day Count: ACT/365
• Denominations: 100kx1k
• Listing: Luxembourg Stock Exchange
• Law: New York
• Sole Global Coordinator and Physical Bookrunner: BNP Paribas (B&D)
• Joint Bookrunners: Banca Akros, CACIB, GS, IMI, JPM, Natixis
• UOP: Refinance existing indebtedness and fund a distribution to parent to repay a portion of the PIK Notes
• Biz: A leading primary care pharmaceutical company in Italy that promotes a well-established and diversified portfolio of leading branded off-patent products
• HQ: Milan, Italy

Marketing:

• Investor Call: GIC 8:30 UKT / 9:30 CET, 16-June-2026
• Q&A Sessions: 16/17-June-2026

https://dealroadshow.com/e/NEO2026 (Access Code: NEO2026)

https://evercall.co/oacc/46099 (GIC Registration)